Randén-Brady, R., Carpén, T., Hautala, L.C. et al. LRG1 and SDR16C5 protein expressions differ according to HPV status in oropharyngeal squamous cell carcinoma. Sci Rep 14, 14148 (2024).
This new study highlights the importance of understanding molecular differences in oropharyngeal squamous cell carcinoma (OPSCC), depending if the tumor is infected with human papillomavirus or not (HPV status).
The study used 4 Triple A Polyclonals primary antibodies from Atlas Antibodies in WB and IHC: the anti-LRG1 (HPA001888), anti-PIP4K2C (HPA028658), anti-SDR16C5 (HPA025224), and anti-MVD (HPA048250).
Results show significant differences in protein expression levels depending on the HPV status of the tumors.
For example, LRG1 protein is highly expressed in HPV-positive OPSCC cases compared to HPV-negative cases, suggesting a potential role in the pathogenesis or progression of HPV-associated cancers.
Conversely, SDR16C5 protein shows higher expression levels in HPV-negative OPSCC, which may be indicative of different molecular pathways involved in HPV-negative tumors.
Clinical Implications:
The differential expression of LRG1 and SDR16C5 proteins based on HPV status could be used as biomarkers to distinguish between HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma (OPSCC).
This distinction is clinically significant because HPV-positive and HPV-negative OPSCC often have different prognoses and may respond differently to treatment modalities such as chemotherapy, radiotherapy, and surgery.
Identifying these biomarkers could not only aid in more accurate diagnosis and classification of the cancer but also help tailor individualized treatment strategies, improving overall patient outcomes and providing more precise prognostic information.
Read the full study